SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

Although a rare subset of non -Hodgkin lymphomas, peripheral T -cell lymphomas (PTCL) account for a disproportionate propor tion of patient mor tality. Conventional therapies are derived from experience treating aggressive B -cell lymphomas and center around CHOP -based chemotherapy. However, due to the unique biology and diverse subtypes of PTCL, most patients fail to durably respond to this approach and 5 -year survival is only 20% to 30%. There have been multiple attempts to improve outcomes for patients with PTCL. Among the more successful strategies are the use of consolidative autologous stem cell transplant, the augmentation of CHOP with etoposide (CHOEP), and the use of brentuximab vedotin in CD30-positive PTCL. Advances in the understanding of histology -specific biology has cultivated enthusiasm to evaluate hypomethylating agents, histone deacetylate inhibitors, and phosphoinositol-3-kinase inhibitors in the frontline setting. Improvements in monitoring disease response and prognostication including the use of cell -free DNA, mutational profiling, and interim PET/CT imaging are also on the horizon. For patients with acute T -cell leukemia/lymphoma, the use of mogamulizumab-based therapy in the frontline setting may lead to advances in care. The true impact of these new -era therapies will only be elucidated as clinical practices incorporate the rapidly changing evidence.